GoodRx vs SkinnyRx
SkinnyRx has an open FDA warning letter dated February 20, 2026. GoodRx has none. On brand-name tirzepatide pen, GoodRx costs $13,212 less a year at standing rates: $299 a month against $1,400 a month at SkinnyRx. It is one of two products the two sell at comparable terms.
To see where both sit among the other sellers, read our best weight-loss injection providers board.
The record
GoodRx / SkinnyRx
GoodRx
7.8/10
Featured pick (affiliate partner)
SkinnyRx
6.3/10
SkinnyRx is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. GoodRx pays us nothing. The scores are computed the same way for both and are shown as computed (GoodRx 7.8, SkinnyRx 6.3). How we are paid
What the record shows
- 01
SkinnyRx has an open FDA warning letter dated February 20, 2026. GoodRx has none.
- 02
SkinnyRx names no compounding pharmacy in our record. GoodRx sells brand-name medication only.
- 03
On brand-name tirzepatide pen, GoodRx costs $13,212 less a year at standing rates: $299 a month against $1,400 a month at SkinnyRx. It is one of two products the two sell at comparable terms.
- 04
Only SkinnyRx lists a price for compounded semaglutide injection, compounded tirzepatide injection and brand-name semaglutide pen.
- 05
GoodRx covers one state SkinnyRx does not.
Prices and terms, product by product
A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.
GoodRx
SkinnyRx
$299/moLower
$3,588 a year
$1,400/mo
$16,800 a year
$149/moLower
$1,788 a year
$248/mo
$2,976 a year
$99/mo
first month only; not compared
$99/mo
first month only; not compared
$1,400/mo
$16,800 a year
$149/mo
first month only; not compared
$199/mo
first month only; not compared
$248/mo
$2,976 a year
Read off each seller’s own pages. GoodRx: October 30, 2026. SkinnyRx: October 30, 2026. Every plan and dose we hold is on the full review.
The case for each
The case for GoodRx
7.8/10- No FDA warning letter on record
- $13,212 a year less on brand-name tirzepatide pen
- $1,188 a year less on Foundayo (orforglipron) pill
The case for SkinnyRx
6.3/10- Sells compounded semaglutide injection and compounded tirzepatide injection, which GoodRx does not price
- Open FDA warning letter, February 20, 2026
- Names no compounding pharmacy
Scores
GoodRx 7.8 · SkinnyRx 6.3 out of 10. Six weighted parts.
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
The score is the same formula for every seller. Payment does not enter it. Method
GoodRx vs SkinnyRx: questions
Other sellers we are paid by
Affiliate partners outside this pair. Each has its own record and review, scored the same way.
- Luvo Health7.9
From $179/mo
Visit site - Gala8.5
From $179/mo
Visit site - HealthRX8.2
From $165/mo
Visit site
Sellers closest to these two
- GoodRx vs Hims
- GoodRx vs Ro
- GoodRx vs Mochi Health
- SkinnyRx vs Found
- SkinnyRx vs ShedRx
- SkinnyRx vs Mochi Health
Matched on molecule, form and price. Every pair we list · The register
Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks